Background
Gross-to-net adjustments have doubled in the past seven years and are squeezing profit margins as distance grows between drug list prices and their net prices after rebates and other reductions. A 1% improvement in GTN can mean millions to the bottom line.
Challenge
Our clients include pharmaceutical companies, big or small, focusing on branded, specialty, and generic segments. Being able to understand, explain, and accurately forecast GTN adjustments is critical to the finance function of commercial pharmaceutical organizations.
Approach
In one centralized solution, capture the impact of market events to forecast in-market volumes; model pricing changes by brand and SKU; perform pre-/post-deal analytics and forecast and measure contract performance; incorporate rebate assumptions; and forecast channel mix and rebates by channel across Commercial, Part D, and Medicaid. Quickly apply changes to methodologies for forecasting GTN.
Key results
Benefits
Simplify gross-to-net complications and confidently model all assumptions around distributor agreements, complex contract terms, and all rebates, chargebacks, and deductions.
Technology partners
Anaplan
Anaplan is a cloud-native enterprise SaaS solution that empowers global organizations to orchestrate business performance and execute digital transformation with confidence and agility.
150+
certified consultants
100+
clients
7+
years of partnership
Share this key play
